Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission

Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission : 5-year follow-up of the IMAGINE-RA randomised trial. / Møller-Bisgaard, Signe; Hørslev-Petersen, Kim; Ørnbjerg, Lykke Midtbøll; Ejbjerg, Bo; Hetland, Merete Lund; Møller, Jakob Møllenbach; Nielsen, Sabrina Mai; Glinatsi, Daniel; Boesen, Mikael; Stengaard-Pedersen, Kristian; Madsen, Ole Rintek; Jensen, Bente; Villadsen, Jan Alexander; Hauge, Ellen Margrethe; Hendricks, Oliver; Lindegaard, Hanne; Krogh, Niels Steen; Jurik, Anne Grethe; Thomsen, Henrik; Christensen, Robin; Østergaard, Mikkel.

In: RMD Open, Vol. 10, No. 1, e003945, 2024.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Møller-Bisgaard, S, Hørslev-Petersen, K, Ørnbjerg, LM, Ejbjerg, B, Hetland, ML, Møller, JM, Nielsen, SM, Glinatsi, D, Boesen, M, Stengaard-Pedersen, K, Madsen, OR, Jensen, B, Villadsen, JA, Hauge, EM, Hendricks, O, Lindegaard, H, Krogh, NS, Jurik, AG, Thomsen, H, Christensen, R & Østergaard, M 2024, 'Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial', RMD Open, vol. 10, no. 1, e003945. https://doi.org/10.1136/rmdopen-2023-003945

APA

Møller-Bisgaard, S., Hørslev-Petersen, K., Ørnbjerg, L. M., Ejbjerg, B., Hetland, M. L., Møller, J. M., Nielsen, S. M., Glinatsi, D., Boesen, M., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Hendricks, O., Lindegaard, H., Krogh, N. S., Jurik, A. G., Thomsen, H., ... Østergaard, M. (2024). Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial. RMD Open, 10(1), [e003945]. https://doi.org/10.1136/rmdopen-2023-003945

Vancouver

Møller-Bisgaard S, Hørslev-Petersen K, Ørnbjerg LM, Ejbjerg B, Hetland ML, Møller JM et al. Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial. RMD Open. 2024;10(1). e003945. https://doi.org/10.1136/rmdopen-2023-003945

Author

Møller-Bisgaard, Signe ; Hørslev-Petersen, Kim ; Ørnbjerg, Lykke Midtbøll ; Ejbjerg, Bo ; Hetland, Merete Lund ; Møller, Jakob Møllenbach ; Nielsen, Sabrina Mai ; Glinatsi, Daniel ; Boesen, Mikael ; Stengaard-Pedersen, Kristian ; Madsen, Ole Rintek ; Jensen, Bente ; Villadsen, Jan Alexander ; Hauge, Ellen Margrethe ; Hendricks, Oliver ; Lindegaard, Hanne ; Krogh, Niels Steen ; Jurik, Anne Grethe ; Thomsen, Henrik ; Christensen, Robin ; Østergaard, Mikkel. / Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission : 5-year follow-up of the IMAGINE-RA randomised trial. In: RMD Open. 2024 ; Vol. 10, No. 1.

Bibtex

@article{200771aa1e2a4d36ab74b46013b3fae8,

title = "Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial",

abstract = "Objective To investigate whether a 2-year MRI treat-To-Target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-To-Target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function. Results In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6-2.2) and vdHSS 16.0 (IQR 7.0-36.0) were included in the study; 59 (59%) patients from the original MRI treat-To-Target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-To-Target group vs 54 patients (75%) in the conventional treat-To-Target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43). Conclusion A 2-year combined MRI and clinical treat-To-Target strategy, compared with a conventional clinical treat-To-Target strategy alone, had no effect on the long-Term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.",

keywords = "Arthritis, Rheumatoid, Inflammation, Magnetic Resonance Imaging, Patient Reported Outcome Measures",

author = "Signe M{\o}ller-Bisgaard and Kim H{\o}rslev-Petersen and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Bo Ejbjerg and Hetland, {Merete Lund} and M{\o}ller, {Jakob M{\o}llenbach} and Nielsen, {Sabrina Mai} and Daniel Glinatsi and Mikael Boesen and Kristian Stengaard-Pedersen and Madsen, {Ole Rintek} and Bente Jensen and Villadsen, {Jan Alexander} and Hauge, {Ellen Margrethe} and Oliver Hendricks and Hanne Lindegaard and Krogh, {Niels Steen} and Jurik, {Anne Grethe} and Henrik Thomsen and Robin Christensen and Mikkel {\O}stergaard",

year = "2024",

doi = "10.1136/rmdopen-2023-003945",

language = "English",

volume = "10",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "1",

}

RIS

TY - JOUR

T1 - Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission

T2 - 5-year follow-up of the IMAGINE-RA randomised trial

AU - Møller-Bisgaard, Signe

AU - Hørslev-Petersen, Kim

AU - Ørnbjerg, Lykke Midtbøll

AU - Ejbjerg, Bo

AU - Hetland, Merete Lund

AU - Møller, Jakob Møllenbach

AU - Nielsen, Sabrina Mai

AU - Glinatsi, Daniel

AU - Boesen, Mikael

AU - Stengaard-Pedersen, Kristian

AU - Madsen, Ole Rintek

AU - Jensen, Bente

AU - Villadsen, Jan Alexander

AU - Hauge, Ellen Margrethe

AU - Hendricks, Oliver

AU - Lindegaard, Hanne

AU - Krogh, Niels Steen

AU - Jurik, Anne Grethe

AU - Thomsen, Henrik

AU - Christensen, Robin

AU - Østergaard, Mikkel

PY - 2024

Y1 - 2024

N2 - Objective To investigate whether a 2-year MRI treat-To-Target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-To-Target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function. Results In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6-2.2) and vdHSS 16.0 (IQR 7.0-36.0) were included in the study; 59 (59%) patients from the original MRI treat-To-Target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-To-Target group vs 54 patients (75%) in the conventional treat-To-Target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43). Conclusion A 2-year combined MRI and clinical treat-To-Target strategy, compared with a conventional clinical treat-To-Target strategy alone, had no effect on the long-Term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.

AB - Objective To investigate whether a 2-year MRI treat-To-Target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-To-Target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function. Results In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6-2.2) and vdHSS 16.0 (IQR 7.0-36.0) were included in the study; 59 (59%) patients from the original MRI treat-To-Target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-To-Target group vs 54 patients (75%) in the conventional treat-To-Target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43). Conclusion A 2-year combined MRI and clinical treat-To-Target strategy, compared with a conventional clinical treat-To-Target strategy alone, had no effect on the long-Term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.

KW - Arthritis, Rheumatoid

KW - Inflammation

KW - Magnetic Resonance Imaging

KW - Patient Reported Outcome Measures

U2 - 10.1136/rmdopen-2023-003945

DO - 10.1136/rmdopen-2023-003945

M3 - Journal article

C2 - 38490697

AN - SCOPUS:85188201631

VL - 10

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 1

M1 - e003945

ER -

ID: 386598355